Skip to main content
    M

    Myriad Genetics Inc (MYGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $5.54
    -0.03 (-0.54%)

    Market Cap: $542.92M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Myriad Genetics Inc (MYGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Myriad Genetics (MYGN) has a market cap of $542.92M and an enterprise value of $556.92M. It kept -16.07% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 2.58% above the market cap, as debt exceeds cash.

    Market Cap$542.92M
    Enterprise Value$556.92M
    Latest price (Nov 17, 2026)$5.54

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.95% in the quarter ended Sep 30, 2026 and grew 2.61% a year over 2 years.

    Shares Outstanding95.70M
    Shares Change (YoY)+2.79%
    Shares Change (QoQ)+0.95%
    Share Count Growth (2Y CAGR)+2.61%

    Valuation Ratios

    Sales and book value multiples are 0.7x and 2.0x. Its year-end P/S ranged from 0.7x to 3.3x from 2016 to 2025.

    P/S Ratio0.7x
    Forward P/S0.7x
    P/B Ratio2.0x
    P/TBV Ratio5.9x

    Valuation history and multiples

    Price Statistics

    The stock is down 17.44% over 52 weeks and trades 14.46% above its 50-day average.

    Beta (1Y)0.63
    52-Week Change-17.44%
    1-Month Change+31.59%
    3-Month Change+73.67%
    6-Month Change+56.06%
    5-Year Change-79.36%
    10-Year Change-67.78%
    Total Return (1Y)-17.44%
    Total Return (3Y CAGR)-32.31%
    Total Return (5Y CAGR)-27.86%
    Return vs SPY (1Y)-28.00%
    Max Drawdown (1Y)-63.84%
    Max Drawdown (3Y)-90.00%
    Sharpe Ratio (1Y)-0.19
    Correlation with SPY (1Y)0.09
    50-Day Average$4.84
    200-Day Average$4.61
    52-Week Range$2.74 to $8.09
    RSI (14 Days)51.3
    Average Volume (20 Days)2.09M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.98x current liabilities, and total debt is 0.45x shareholder equity.

    Current Ratio1.98x
    Quick Ratio1.77x
    Debt / Equity0.45x
    Interest Coverage-6.89x

    Returns and Efficiency

    Return on invested capital is -29.46% over the last 12 months, against a 5-year average of -27.55%.

    Return on Equity (ROE)-47.99%
    Return on Assets (ROA)-21.19%
    Return on Invested Capital (ROIC)-29.46%
    Return on Capital Employed (ROCE)-24.39%
    ROE (5Y Average)-33.33%
    ROA (5Y Average)-19.71%
    ROIC (5Y Average)-27.55%
    Asset Turnover1.20x
    Inventory Turnover8.60x
    Receivables Turnover7.48x
    Cash Conversion Cycle50 days

    Scores

    MYGN has an Altman Z-Score of -0.96, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.96
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $803.60M over the last 12 months is down 2.63% from the 12 months before.

    Revenue$803.60M
    Revenue Growth (YoY)-2.63%
    Gross Profit$549.10M
    Operating Income-$115.20M
    Pretax Income-$129.20M
    Net Income-$129.10M
    EBITDA-$64.80M
    EBIT-$115.00M
    Reported EPS (TTM)-$0.59

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 44.16% of the $609.20M in total assets.

    Cash and Equivalents$107.10M
    Total Debt$121.10M
    Net Debt$14.00M
    Net Debt Per Share$0.15
    Working Capital$134.30M
    Shareholder Equity$269.00M
    Book Value Per Share$2.81
    Tangible Book Value$90.10M
    Tangible Book Per Share$0.94
    Total Assets$609.20M
    Total Liabilities$340.20M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $14.00M of capital spending, operating cash flow left -$33.90M of free cash flow.

    Operating Cash Flow-$19.90M
    Capital Expenditures$14.00M
    Free Cash Flow-$33.90M
    FCF Per Share-$0.35
    Depreciation and Amortization$50.20M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -14.34%, against a 5-year average of -28.84%.

    Gross Margin68.33%
    Operating Margin-14.34%
    Pretax Margin-16.08%
    Net Margin-16.07%
    EBITDA Margin-8.06%
    EBIT Margin-14.31%
    FCF Margin-4.22%
    Gross Margin (5Y Average)70.02%
    Operating Margin (5Y Average)-28.84%
    Net Margin (5Y Average)-23.00%

    Growth

    Revenue grew 6.72% a year over 3 years.

    Revenue Growth (3Y CAGR)+6.72%
    Book Value Per Share Growth (2Y CAGR)-34.15%
    Tangible Book Per Share Growth (2Y CAGR)+1.40%

    Revenue and profit by year

    Dividends and Yields

    MYGN does not pay a dividend. Its free cash flow yield is -6.39%.

    FCF Yield-6.39%
    Buyback Yield-0.11%
    Shareholder Yield-0.11%

    Stock Splits

    The last split was a 2-for-1 forward split on Mar 26, 2009.

    Last Split DateMar 26, 2009
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 11 similar companies, MYGN has the lowest P/S.

    P/S Ratio0.7x vs 3.4x median
    ROIC-29.46% vs -5.68% median
    Revenue Growth (Trailing 4 Quarters, YoY)-2.63% vs +17.18% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -6.57% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-6.57%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MYGN

    What is MYGN's market cap?

    Myriad Genetics has a market cap of $542.92M. Its enterprise value, which adds debt and subtracts cash, is $556.92M.

    How many shares of MYGN are outstanding?

    Myriad Genetics has 95.70M shares outstanding. The count is up 2.79% from a year earlier.

    Does MYGN pay a dividend?

    No. Myriad Genetics does not pay a dividend.

    How much debt does MYGN have?

    Myriad Genetics has $121.10M of total debt and $107.10M of cash and equivalents, a net debt position of $14.00M.